An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new round of comparisons between weight-loss drugs is getting attention: researchers, reporters and doctors are looking at how three leading medicines stack up — semaglutide (sold as Ozempic/Wegovy), tirzepatide (Zepbound/Mounjaro) and an experimental one called retatrutide. The loose verdict so far is that tirzepatide and retatrutide seem to cause more weight loss than semaglutide in the studies we’ve seen, but those differences come with caveats about who was studied and what we still don’t know. Semaglutide is a man-made version of a natural gut hormone that helps control appetite and slows how fast the stomach empties. That’s why drugs like Wegovy and Ozempic (which both use semaglutide) reduce hunger and help people eat less. Tirzepatide is a newer drug that activates two hormone pathways instead of one: it acts like both the gut hormone used by semaglutide and another hormone that helps regulate blood sugar and appetite. Retatrutide is an experimental compound that hits three related pathways and is designed to increase the appetite-suppressing and metabolism effects even more. The actual studies show differences in how much weight people lost in clinical trials. Large trials of semaglutide produced strong results — many people lost significant weight compared with placebo. Tirzepatide trials generally reported bigger average weight loss than semaglutide in head-to-head studies, and retatrutide’s early trials reported even larger losses for some participants. But keep in mind: semaglutide and tirzepatide have large phase 3 trial programs and are approved for weight management, while the retatrutide data come from earlier-stage research with fewer people and shorter follow-up. Numbers vary by study, population, dose and how long people stayed on the drug. Why this matters: obesity and overweight are common, and these drugs can help people lose weight when diet and exercise alone haven’t worked. A medicine that helps someone lose 15–25% of body weight can reduce the risk of diabetes, lower blood pressure and improve quality of life for many. If newer drugs reliably produce larger losses, they could change medical treatment for obesity and reduce the need for surgical options for some people. There are important caveats and risks. Side effects are common and usually involve the gut — nausea, vomiting, diarrhea and constipation. Rare but serious risks include inflammation of the pancreas and gallbladder issues. Long-term safety beyond a few years is still being studied, especially for newer agents like retatrutide. These drugs are prescription medicines and not appropriate for everyone: people with certain medical histories, pregnant people, and those with some rare conditions shouldn’t use them. Also, cost and access remain big issues; newer drugs can be expensive and may not be covered by insurance. Bottom line: newer drugs like tirzepatide and experimental triple-acting compounds look more powerful than semaglutide in trials so far, but real-world safety, long-term effects and wider availability are still unresolved.
Source: www.polskieradio.pl